Literature DB >> 29181544

Angiotensin 1-7, but not the thrombin-cleaved osteopontin C-terminal fragment, attenuates osteopontin-mediated macrophage-induced endothelial-cell inflammation.

Rachel Hamias1, Assaf Rudich2,3, George Greenberg4, Gabriel Szendro4, Talya Wolak5.   

Abstract

OBJECTIVE AND
DESIGN: Evaluating the pro-/anti-inflammatory activity of the C-terminal cleavage product of osteopontin in comparison to angiotensin 1-7. MATERIAL AND
SUBJECTS: Human coronary endothelial cells (hcEC) treated with conditioned media from human U937 macrophages. TREATMENT: Macrophages were (pre)treated with C-terminal, full-length or N-terminal osteopontin (OPN-C, OPN-FL, OPN-N, respectively), angiotensin II, angiotensin 1-7 or TNF-α. OPN-C modulatory capacity was compared to that of Ang1-7 in inhibiting subsequent Ag II, OPN-FL or OPN-N-induced macrophage-mediated endothelial inflammation.
METHODS: Protein expression of NFκB, IκB, vCAM-1 and iCAM-1 was assessed using western blot. Promotor activation by NFκB was also assessed by dual-luciferase reporter assay.
RESULTS: Conditioned media of macrophages treated with OPN-C induced hcECs' NfκB activation to a lower degree than OPN-FL or OPN-N. Priming of macrophages with angiotensin 1-7 attenuated the endothelial pro-inflammatory effect induced by subsequent exposure of the macrophages to angiotensin II, OPN-FL or OPN-N. This was evidenced by both NfκB activation and vCAM and iCAM expression. In contrast, priming macrophages with OPN-C did not significantly attenuate the subsequent response to the pro-inflammatory cytokines.
CONCLUSIONS: OPN-C induces lower macrophage-induced endothelial inflammation compared to OPN-FL or OPN-N, but unlike angiotensin 1-7, fails to prevent endothelial inflammation induced by subsequent pro-inflammatory macrophage stimulation.

Entities:  

Keywords:  IκB; NFκB; OPN-C terminal; OPN-N terminal; Osteopontin

Mesh:

Substances:

Year:  2017        PMID: 29181544     DOI: 10.1007/s00011-017-1120-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  40 in total

Review 1.  Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.

Authors:  Riku Das; Subha Philip; Ganapati H Mahabeleshwar; Anuradha Bulbule; Gopal C Kundu
Journal:  IUBMB Life       Date:  2005-06       Impact factor: 3.885

2.  Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragment.

Authors:  Zhifei Shao; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

3.  Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin).

Authors:  R Agnihotri; H C Crawford; H Haro; L M Matrisian; M C Havrda; L Liaw
Journal:  J Biol Chem       Date:  2001-05-25       Impact factor: 5.157

4.  Plasma thrombin-cleaved osteopontin as a potential biomarker of acute atherothrombotic ischemic stroke.

Authors:  Saya Ozaki; Mie Kurata; Yoshiaki Kumon; Shirabe Matsumoto; Masahiko Tagawa; Hideaki Watanabe; Shiro Ohue; Jitsuo Higaki; Takanori Ohnishi
Journal:  Hypertens Res       Date:  2016-08-25       Impact factor: 3.872

5.  SVVYGLR motif of the thrombin-cleaved N-terminal osteopontin fragment enhances the synthesis of collagen type III in myocardial fibrosis.

Authors:  Ayako Uchinaka; Yoshinosuke Hamada; Seiji Mori; Shigeru Miyagawa; Atsuhiro Saito; Yoshiki Sawa; Nariaki Matsuura; Hirofumi Yamamoto; Naomasa Kawaguchi
Journal:  Mol Cell Biochem       Date:  2015-06-27       Impact factor: 3.396

6.  Distinct roles of osteopontin fragments in the development of the pulmonary involvement in sarcoidosis.

Authors:  K Maeda; K Takahashi; F Takahashi; N Tamura; M Maeda; S Kon; T Uede; Y Fukuchi
Journal:  Lung       Date:  2001       Impact factor: 2.584

7.  Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma.

Authors:  Jennifer Sullivan; Laurel Blair; Amer Alnajar; Tamer Aziz; Chee Yuan Ng; Galina Chipitsyna; Qiaoke Gong; Agnes Witkiewicz; Georg F Weber; David T Denhardt; Charles J Yeo; Hwyda A Arafat
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

8.  Oxidized low-density lipoprotein increases the proliferation and migration of human coronary artery smooth muscle cells through the upregulation of osteopontin.

Authors:  Jun Liu; Yingang Ren; Li Kang; Lihua Zhang
Journal:  Int J Mol Med       Date:  2014-02-28       Impact factor: 4.101

9.  Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.

Authors:  R Raja; S Kale; D Thorat; G Soundararajan; K Lohite; A Mane; S Karnik; G C Kundu
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

10.  Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo.

Authors:  Elena Boggio; Chiara Dianzani; Casimiro Luca Gigliotti; Maria Felicia Soluri; Nausicaa Clemente; Giuseppe Cappellano; Erika Toth; Davide Raineri; Benedetta Ferrara; Cristoforo Comi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  J Immunol Res       Date:  2016-07-13       Impact factor: 4.818

View more
  2 in total

1.  Saturated fatty acids bound to albumin enhance osteopontin expression and cleavage in renal proximal tubular cells.

Authors:  Alyssa Cobbs; Kristopher Ballou; Xiaoming Chen; Jasmine George; Xueying Zhao
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-03-10

2.  Role of p120 Catenin in Epac1-Induced Chronic Postsurgical Pain in Rats.

Authors:  Peng Pan; Sai-Sai Huang; Shi-Ren Shen; Cui-E Lu; Yi-Bin Qin; Jia-Long Zhang; Su Cao
Journal:  Pain Res Manag       Date:  2019-02-03       Impact factor: 3.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.